Covance Appoints VP of Clinical Development Services - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Covance Appoints VP of Clinical Development Services



Covance reported that Barry J. Goldstein, MD, PhD, has joined its clinical development services business as vice-president and global therapeutic area head of the expanded cardiovascular, metabolic, endocrine, and renal unit.  In this new role, Goldstein will join the medical & scientific affairs leadership team and will be based in Princeton, NJ.
 
Goldstein joins Covance from Merck where he served as vice-president in clinical research and therapeutic area head for diabetes and endocrinology, since 2008.  In this role, he managed Merck’s Phase II-IV clinical development team for a large portfolio including diabetes, obesity, osteoporosis, and women’s health.  His responsibilities included strategic input to proof-of-concept study designs, clinical trial strategies, protocol development, regulatory filings, responses to payer inquiries, lifecycle management activities, as well as pharmacovigilance and post-marketing studies. In addition to his biopharmaceutical industry experience, Goldstein’s medical career includes serving as director, division of endocrinology, diabetes & metabolic diseases, Jefferson Medical College at Thomas Jefferson University in Philadelphia from 1992 to 2008.  His most recent academic roles include professor of medicine, biochemistry and molecular pharmacology at Jefferson from 1997 to 2008.
 
Source: Covance

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here